This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Viral Infections  • Sexually Transmitted Diseases  • Immunotherapy  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Human papillomavirus (HPV) infections of the anogenital tract belong to the most common group of sexually transmitted diseases worldwide. So far, more than 90 different HPV types have been isolated from cutaneous and mucosal lesions.¹ Mucosal HPV-6 and -11 are the most frequent types found in patients with genital warts or condylomata acuminata (CA).² In human immunodeficiency virus (HIV)–infected individuals, standard therapies for CA often fail, probably because of the suppressed cellular immune response leading to an insufficient control and increased replication of HPV.^3-4 In this context, intra-anal CA in HIV-infected men represents a special therapeutic challenge, as both ablation and follow-up are difficult to perform because of the local anatomical situation. Imiquimod, a topical immune response modifier, has been approved for the treatment of CA in the United States and Europe. In 2002, Kaspari et al⁵ reported that the use of suppositories containing imiquimod successfully prevented recurrences of intra-anal . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION
Alexander Kreuter, MD; Norbert H. Brockmeyer, MD; Soenke J. Weissenborn, PhD; Arasch Wafaisade; Herbert Pfister, PhD; Peter Altmeyer, MD; Ulrike Wieland, MD for the German Competence Network HIV/AIDS